Kala Bio (KALA) Cash from Operations (2016 - 2026)

Kala Bio has disclosed Cash from Operations across 11 years of filings, most recently posting -$1.5 million for Q2 2026.

• In Q2 2026, Cash from Operations rose 90.73% year-over-year to -$1.5 million; the TTM figure through Jun 2026 stood at -$19.9 million (up 42.77% YoY), while the FY2025 annual figure was -$32.0 million, down 8.88% from the prior year.
• Cash from Operations came in at -$1.5 million for Q2 2026 at Kala Bio, up from -$2.9 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$1.5 million in Q2 2026 to a low of -$25.4 million in Q2 2022.
• Average Cash from Operations over 5 years is -$10.1 million, with a median of -$9.0 million recorded in 2024.
• Year-over-year, Cash from Operations slumped 130.2% in 2025 and soared 90.73% in 2026.
• Over 5 years, Cash from Operations stood at -$13.7 million in 2022, then soared by 43.97% to -$7.7 million in 2023, then soared by 40.25% to -$4.6 million in 2024, then gained by 0.91% to -$4.6 million in 2025, then surged by 66.31% to -$1.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$1.5 million in Q2 2026, -$2.9 million in Q1 2026, and -$4.6 million in Q4 2025.